Piran Sucindran is Head of Quality at Blue Earth Therapeutics, a clinical stage radiopharmaceutical company focussed on targeted radiotherapeutics. Piran has previous experience of leading global quality and regulatory teams within an Imaging CRO, and prior to that worked as quality lead at a number of sites within the NHS. He is a member of the Research Quality Association (RQA) GCP Committee, Research Practitioners' Group, and lead on the 'Clinical Oversight of Computerised Systems' seminar."

Laura Clifton-Hadley is Head of Clinical Operations, Northern Europe, based in the UK. She leads all clinical trial and late development activities across the Bristol Myers Squibb portfolio. Laura is an experienced leader, with experience in all phases of trials and therapeutic areas. Prior to BMS, she worked as the head of haematology and brain trials at University College London. She has more than 14 years of clinical operations experience, and more than 12 years of line management experience. She sits on various UK and IE industry bodies/government bodies to promote/facilitate commercial clinical research and to ensure that we are bringing the right studies to the UK and IE.
Laura received her PhD in microbiology from the University of Reading. She also holds an honours degree in microbiology and virology from the University of Warwick.

Richard Stephens has been a patient advocate for 25 years, surviving two cancers and a heart emergency, plus several co-morbidities and late effects. As a patient he has participated in four interventional studies and nine others. As an Advocate he has helped design over 30 more.

Richard Chairs the UK Cancer Research Advocates Forum (formerly the NCRI Consumer Forum) and is the former Chair of BBMRI-ERIC’s Stakeholder Forum. He works with patient groups and advocates, academics and industry, and policy-makers, funders and regulators.  

Richard helped found the AllTrials campaign and useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement. His professional life has included careers in education, journalism and local government.

An experienced executive leader within the pharmaceutical industry with a clear focus on and passion for developing high performing cross-functional teams who work without barriers. Highly inclusive yet decisive, adaptable and with a track record of high quality delivery whilst motivating and inspiring the teams around me.

A GMC registered, NHS trained medical doctor with pharmaceutical industry experience across a broad range of therapeutic areas working with both pre-launch and in-market products in the UK and Europe. Known for being commercially astute and a strong cross-functional worker with 10 years of management experience up to a team size of 120 striving always to create a rewarding, high energy environment for my teams.

Victoria has worked at Eli Lilly and Company for 16 years across drug safety and clinical operations. In her current role, she leads a team of Clinical Research professionals who work to identify, evaluate, and set up investigator sites across the UK and Nordics. They are responsible for delivery of patients into trials, by forging close site relationships, across the full Lilly portfolio. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are advancing new discoveries to address some of the world's most significant health challenges.

Dr Rebecca Clark is a Partner at Fylde Coast Clinical Research at Layton Medical Centre, a dedicated commercial trials centre in Blackpool. She is a highly experienced trialist with over 70 Phase II/III clinical trials conducted over the last 13 years, with multiple studies as Chief Investigator in the therapy areas of vaccines, obesity medicine, cardiovascular medicine, asthma and diabetes. She holds a number of senior leadership roles including co-clinical lead for the UK Vaccine Innovation Pathway, a UK clinical trials accelerator.

Fylde Coast Clinical Research at Layton Medical Centre recruits amongst the highest number of commercial participants across the NHS in England and was in the top 1% of NHS recruiting sites when compared with all 637 sites across both primary and secondary care in 22/23. Study participant retention rates exceeded 99%. Her site regularly achieves UK FPV and she is renowned for accelerated set up and recruitment timelines, experience she is now bringing to her role in the UK VIP.

Fylde Coast Clinical Research currently holds contracts with Eli Lilly, Moderna, Astra Zeneca, Roche, Amgen, Merck, Novo Nordisk and GSK, with whom they are members of the PEER preferred site network.

Dr Clark continues to be recognised nationally for her excellence in clinical trial delivery, being a former recipient of the Gold Award for Clinical Site of the Year at the Pharmatimes International Clinical Researcher of the Year.

Catherine Mela is Executive Director, Head of Precision Medicine Operations, within GSK. In her role, Catherine is accountable for leading the Scientific Operations and Data Operations teams, driving the execution of precision medicine project strategies with efficiency and quality.

Catherine has gained broad experience in laboratory and bio-sample operations, while leading sampling and laboratory operations teams in AstraZeneca and Roche.

Prior to working in pharma, Catherine’s background was in Clinical research within the NHS.  She holds a PhD from Imperial College on ‘The impact of treatment strategies on immune responses in HIV-1 infection’.  Catherine is a fellow of the institute of leadership and is passionate about professional development, mentorship and creating a supportive environment for individuals within her teams.

With over 40 years of experience in the clinical research industry, I’ve had the privilege of working in large pharma, biotech, and CRO environments. I began my career as a Clinical Research Associate and have since held a broad range of leadership, operational, and commercial roles, gaining extensive global experience in clinical development, business development, outsourcing, and contracting.

 My therapeutic expertise spans multiple areas including CNS, cardiovascular, ophthalmology and hepatology, with a strong focus over the past decade on the development of advanced therapy medicinal products (ATMPs), particularly cell and gene therapies.

 I am currently the Vice President of Clinical Operations at Resolution Therapeutics Limited, a pioneering UK-based biotechnology company developing regenerative macrophage cell therapies. I remain deeply passionate about clinical research, am a committed advocate of the UK biotech sector, and am firmly driven by the mission to help bring innovative medicines to patients worldwide.

Fiona chairs the Sustainable Healthcare Coalition that inspires partnerships and action on sustainable healthcare. She also works as an independent expert advisor and board member for national and global organisations on wellbeing and sustainability.

She is a high-profile wellbeing and public health leader with a track record of reframing thinking and developing innovative strategy and programmes at the heart of business and government. Her previous roles include Deputy Chief Medical Officer and Director General in the UK Government, Director of Chronic Disease and Health Promotion at the World Health Organisation and Bupa’s Chief Wellbeing Officer.

Fiona is a visiting Professor at UCL and is a Senior Associate at Cambridge Institute for Sustainability Leadership.  Fiona’s recent board roles include Fresenius ESG Advisory Board, My Green Lab, British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team. Fiona is a member of the Health System Taskforce of the Sustainable Markets Initiative.

Blanka is an Associate Director within Precision Medicine Scientific Operations at GSK with over ten years of experience in research spanning from clinical site to sponsor roles, and expertise in biosample operations. She leads operational aspects of trials with a focus on innovation and excellence, successfully managing complex clinical studies while ensuring compliance and participant protection. Herf passion lies in ethical research and strategic improvements for operational efficiency.

Experienced strategic leader with extensive experience of operations, business transformation and introducing digital systems. Systems-thinker with focus on delivering cross-sector improvement. Deep knowledge of health and care research regulation and governance.

Julie is the Chief Commercial Office at Deallus, a market leading strategy consultancy, which was acquired by Global Data  at the beginning of the year. Julie's career in life sciences spans 20 years with a focus on partnering with clients on strategy development on local, regional and global level . For more than decade Julie has led large global and regional competitive mindset training programmes for large pharma. Since 2017 Julie has regularly been engaged as an inspirational speaker on Competitive Mindset across brand, portfolio and corporate audiences. Her expertise includes clinical and commercial planning, brand & portfolio strategy  as well as advising organisation  on personalised healthcare approaches across various disease areas.  Julie holds a PhD in Neuroscience from Imperial College London sponsored by Pfizer.

• Fellow of the Royal College of Ophthalmologists
• Medical Retina Sub-specialist in a busy, multi-cultural teaching hospital
• Strong academic background in medical retina with expertise in commercial and non-commercial clinical trials
• Teacher and trainer committed to clinical excellence

Dr. Claudia Hesselmann, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.

Sarah is a clinical research professional with over 25 years of international experience spanning the medical device, pharmaceutical, biotech, and CRO sectors. Her background includes a strong focus on leadership in clinical operations, site engagement, and patient recruitment strategies across diverse therapeutic areas including oncology, infectious diseases, immunology, and vaccines.

Sarah has recently joined Autolus as Director of Clinical Site Engagement, where she will be supporting the planning and execution of site engagement strategies to drive clinical trial success. Prior to this, she served as Regional Director for Clinical Site Management & Monitoring (EU/UK) at Moderna, and held global and regional leadership roles at Biogen, AbbVie, Novartis, Janssen-Cilag and IQVIA, driving patient-centric trial strategies and enhancing site performance.

Sarah lives in the Cotswolds with her three daughters and two dogs, and in her spare time, practices yoga as much as possible.

Dr Puja Myles is Director of the Medicines and Healthcare products Regulatory Agency’s (MHRA) specialist real world data research service, the Clinical Practice Research Datalink (CPRD). She is a public health specialist and prior to joining CPRD, was a public health academic at the University of Nottingham, UK. She is a fellow of the Faculty of Public Health (UK), a senior fellow of the Higher Education Academy (UK) and has a doctorate in epidemiology. She has been the MHRA’s strategic lead on the development of synthetic data generation approaches and applications since 2017. In addition, she has led on Regulatory Science initiatives including AI explainability, handling concept drift, data quality standards for regulatory purposes, regulatory evidence derived from computer modelling and simulation approaches.

Professor Lucy Chappell FMedSci is the Chief Scientific Adviser for the Department of Health and Social Care (DHSC), with overall responsibility for the department’s research and development, including the National Institute for Health and Care Research (NIHR), the government’s major funder of clinical, public health, social care and translational research.

Reporting to the Chief Medical Officer, the Chief Scientific Adviser provides science advice and analysis to ministers across the range of health topics and is involved in cross-government science policy.

Professor Chappell is Professor of Obstetrics at King’s College London, Honorary Consultant Obstetrician at Guy’s and St Thomas’ NHS Foundation Trust and an NIHR Senior Investigator. She will undertake the Chief Scientific Adviser role on secondment into government, while continuing some of her clinical and academic work.

DHSC Chief Scientific Adviser

Innovation-driven clinician and an enterpreneurial enthusiast based at the Manchester Academy of Health Sciences Centre, Manchester University Hospitals. Recognised as an influential health technology leader with major contributions to innovation in healthcare technology, dialysis and delivery systems.

Passionate about transforming clinical services and patient pathways through enabling technology.

In various leadership roles as Deputy Director of NIHR MedTech Cooperative Devices for Dignity, Vice Chair for EUDIAL, ERA-EDTA, Chair of the Haemodialysis Study group for UK Kidney Research Consortium. Driving safe and value based health care with national organisations as CQC Speciality Advisor, and as Clinical Reference Group Member for NHS England.

Managing a diverse portofolio of translational clinical academic research with a global network of collaborators. A trainer, educator and mentor for health professionals at the University of Manchester. Several publications, patents, authored book chapters and media reports of the work in the field.

Maria Koufali, is an experienced senior leader in life sciences research and innovation, bringing over 20 years of cross-sector expertise in working with global pharmaceutical companies, digital health firms, diagnostics developers, and MedTech SMEs. She holds a PhD in Pharmacology and Neuroscience, an MBA (Distinction), and is the first NHS R&D Director nationally to be awarded the Nye Bevan Executive Health Leadership Award. Maria currently leads the UK Vaccine Innovation Pathway at NIHR/DHSC, a nationally mandated clinical trials accelerator. In this role, she has delivered over 20 high-priority commercial trials, expanded partnerships beyond Moderna and BioNTech to include smaller biotech firms and large pharma, and embedded site-readiness models and trial metrics to support faster delivery.

Maria has built a wide network of trusted relationships across the life sciences sector and has consistently translated strategic ambition into operational delivery, regulatory compliance, and commercial value. Previously, as Managing Director of Research & Innovation at Nottingham University Hospitals NHS Trust, she designed and delivered the Trust’s entire NIHR infrastructure portfolio from the ground up, securing funding and oversight for a £70m suite including a BRC, CRF, BioResource, and the Medical Technologies Innovation Facility (MTIF)—a £23m translational platform that supports SMEs to take digital and MedTech innovations from prototype to trial. Under her leadership, the Trust’s commercial research income rose to over £13m per year. She has successfully navigated and aligned MHRA, HRA and ISO frameworks to support industry delivery at scale. Maria currently serves as Trustee and Chair of the Industry Advisory Board at the BBSRC-funded Quadram Institute, where she shapes translational and commercial strategy. She brings a proven ability to develop national infrastructure, deliver commercial growth, and work across government and industry to accelerate innovation that benefits patients and the UK economy.

Peter Morley is leading the global effort to assess and reduce the environmental impact of Novo Nordisk clinical trials globally. He represents Novo Nordisk on the Sustainable Markets Initiative Health Systems Task Force (Digital Healthcare in Clinical Research), collaborating with industry and academia to accelerate the decarbonisation of the clinical trials sector through shared frameworks and tools.

With a background spanning more than 25 years in clinical operations, Peter combines his passion for sustainability with a sharp focus on innovation and digitalisation. This positions him at the forefront of setting the path for decarbonisation and driving the necessary changes to significantly lower the environmental impact of clinical trials.

Suki Balendra a senior leader in the NHS with a 20-year background in facilitating, growing, and promoting health research in the U.K.  She has substantial, in-depth experience across sectors including industry, academia, NHS, and central government.

She is currently the Director of Strategic Partnerships for Imperial College Healthcare NHS Trust in Northwest London. She leads the strategic work with the Life sciences industry in the region with an emphasis on a new life sciences cluster in Paddington. Suki created and leads the North West London Clinical Trials Alliance. She started her career in the Biotechnology Industry at Abbott Diagnostics Ltd. Within a Good manufacturing practice (GMP) environment she worked on several operational projects to improve efficiency, cost, and reproducibility.

In 2018 she was seconded to the Office of Life Sciences within the Department of Business and Industrial Strategy. where she attracted and negotiated new business to increase the UK’s market share of health and care research activity. During the pandemic she provided operational leadership to the NHS covid vaccine research response in Northwest London.

Suki has PhD from the University of Warwick, and she is accredited to black belt in Lean Six Sigma. She is a passionate advocate for UK PLC as the number one destination to conduct clinical trials.

Amelia joined the Parkinson’s Europe  team in Jan 2022 as Research Manager. Since then she has developed Parkinson’s Europe’s Research Strategy, embedding a Research Steering Group into the organisation and helping to increase the presence of Parkinson’s Europe in the clinical research world. She is also focused on bringing new initiatives to the table, such as the Parkinson’s Europe’s Engagement Network, which better connects the Parkinson’s

community with research across Europe. Parkinson’s Europe is now a partner member of EUPATI and the Critical Path for Parkinson’s as part of this action.

She has been working in the field of Neurodegenerative research since 2009 and is a Patient Organisations board member with EUPATI since Sept 2023.

She previously worked for the UK NIHR’s DeNDRoN delivering clinical trials and then at Parkinson’s UK from July 2015 as Research Participation Lead.  She was responsible for initiatives to increase research participation for people affected by Parkinson’s, health care professionals and researchers, and created the innovative Parkinson’s UK Take Part Hub and co-produced the Staying Connected toolkit in collaboration with the HRA UK.

Joe Sutton is a Biosample Project Leader at Roche based in the UK. He leads the operational activities relating to clinical biosampling including centralised screening, safety and biomarker analysis. In this role, Joe influences PhI/II clinical trial design across oncology, neurology and rare disease indications and ensures biosampling plans and biomarker strategies bring optimal value, insights and patient centricity. Prior to working with Roche, Joe worked as a consultant at A4PBio and as a Senior Pharmacology Scientist at GW Pharmaceuticals. Before joining the pharmaceutical industry, Joe completed academic research focusing on therapeutic resistance mechanisms of prostate cancer at University of Cambridge (CRUK Institute) and for completion of his PhD from Edinburgh Napier University.

Marie Lefebvre is a Local Innovation Lead at Sanofi, specializing in developing and implementing innovative strategies to optimize clinical trials. With a Master's degree in Physiology and Computer Sciences from Poitiers University, Marie brings extensive experience in digital project management and clinical operations to her role. At Sanofi, she leads the development and implementation of the UK Clinical Operation Innovation Road Map, focusing on gap analysis, change management, and the adoption of cutting-edge technologies. Beyond her professional achievements, Marie is passionate about sustainability, serving as a Climate Fresk facilitator and actively participating in various environmental initiatives within the industry.

Rajinder Sidhu is the Associate Director for Research Governance and Operations for University College London Hospitals (UCLH) and University College London (UCL) Joint Research Office.  She leads on the necessary governance, policies, and operations for both the sponsorship of studies at UCL and UCLH (ranging from clinical trials and advanced therapies through to observational and data programmes) and the systems and infrastructures required to host research at UCLH (commercial and non-commercial). Rajinder has over 17 years’ experience in senior operational and governance roles at UCLH/UCL and has led large change programmes to streamline systems and embed leaner ways of working across the organisation.

Prior to UCLH/UCL, Rajinder worked for Kings College London, Institute of Psychiatry as a researcher/coordinator for regional research studies into mental health services, and as a manager of international research centres. Rajinder also completed a PhD on consumerism within the NHS at Royal Holloway, University of London.

Fiona has worked within the Life Sciences and Healthcare domain for over 25 years working across GxP areas within the private and public sector environments.

Fiona is currently a Senior Director at Medidata with a focus on quality management and general regulatory compliance and advocacy on topics within the good clinical practice domain.

Over the past few years she has been chairing a number of trade association groups on topics such as new technologies in clinical trials, decentrialised clinical trials and a contributor to EU Artificial Intelligence initiatives.

Prior to Medidata Fiona was a Director at Deloitte, where she led the Deloitte Global Centre for Regulatory Excellence for Life Sciences and provided governance of Deloitte services to the European Medicines Agency and their programmes.

Fiona has a BSc in Chemistry and Management Science and an MSc in Chemistry

With 20 years of global clinical research experience, Paula specialises in accelerating clinical trial delivery, optimising recruitment, and fostering strong site partnerships to ensure high-quality, efficient trial execution. Passionate about site engagement and strategic collaboration, she work closely with key stakeholders across the clinical trial ecosystem to drive performance, mitigate risks, and enhance trial delivery.

Isabel is a Market Solutions Specialist at Optum UK, specialising in clinical trials and real-world evidence with a focus on EMIS Web primary care data and systems. She supports the UK’s only clinical trial recruitment solution fully embedded within the GP clinical system, enabling faster, more accurate patient recruitment while reducing the burden on sites.

Kento Nakamura is a global professional having worked both in the Western and Eastern healthcare landscapes. He has been in various roles, contributing significantly to drug development, market access, and pharmaceutical marketing.

At CMIC, Japan and South Korea’s first CRO, Kento wears multiple hats including helping formulate corporate strategy, creating mutually beneficial partnerships with other companies, and taking initiative to create business development opportunities.

During his tenure at KM Pharmaceutical Consulting, a boutique drug development consulting firm, Kento co-pioneered the market access perspective on drug development, resulting in key additional endpoints in an ongoing phase 2 study. He also played a crucial role in developing the global drug safety plan, ensuring compliance with reporting requirements across multiple continents.

Kento holds an MPH in Health Management from Harvard University and a BS in Biology from Tufts University. He is fluent in English and proficient in Japanese. In his free time, Kento enjoys playing tennis, watching football, visiting contemporary art museums, and traveling around the world.

Dr Davy Yeung’s career to date encompasses academia and the NHS. He has made valuable contributions to clinical research at the University of Cambridge, Imperial College, and other major academic institutions.

Dr Yeung was also the Head of Research at various UK Hospital Trusts. During his time in the NHS, he gained considerable insight into the governance and delivery of clinical research in the UK. This unique perspective enables our sponsors to select, initiate and manage UK investigative sites for their clinical studies rapidly and effectively. Having collaborated with a wide range of influential leaders in the field of clinical research, Dr Yeung is himself highly respected and well known in the UK’s healthcare research and development sector.

Flo is an expert eCOA scientist who has spent her career advising and guiding organizations on the electronic capture of clinical outcome assessments (COA) and the use of digital health technologies (DHTs) in clinical trials. She has a deep knowledge of clinical research, study design, and leveraging technology to support it, having worked at the intersection between science and technology to navigate for better solutions.

Flo actively participates in industry consortia, regularly publishes, and presents at international conferences. She uses her passionate and progressive mindset for driving positive change in the industry, focusing on optimising clinical trial data capture to enhance the participant and site experience.

At uMotif, she provides Scientific Leadership across the organization, ensuring that the scientific voice is embedded across all functional areas to inform rigorous scientific practices. She previously held positions at Signant Health, Medable, and ObvioHealth.

Flo holds an MSc and PhD in Social, Genetic, and Developmental Psychiatry from Kings College London – which included the development of a new PRO.

Tariq is a Lead Clinic Trial Liaison at Regeneron responsible for expanding the clinical trial footprint in the region, providing key scientific insights and overseeing the successful delivery of oncology trials. With over 15 years of Oncology research experience, his leadership and strategic insight have fostered strong collaborations with the NHS, Private Hospitals, and research bodies such as the NIHR and Cancer Trials Office (Ireland).  These partnerships have driven impactful initiatives, with a view to significantly advancing oncology clinical research across UK and Ireland.

Dr Rebecca Ghosh is a Real-World Evidence Specialist in the Scientific, Data and Insight group at the MHRA where she is leading the MHRA the Real-World Evidence Scientific Dialogue Programme and Real-World Data Guidance series.  She has over 15 years experience working as an epidemiologist specialising in public health research using real-world data for a range of observational studies, spatial epidemiology and interventional research.  Rebecca holds an MSc in Public Health from the LSHTM and a PhD in epidemiology from Imperial college.

Steven Sanghera is the Chief Executive Officer (CEO) of Inventus Group Limited, a UK-based technology company specializing in providing fully provisioned mobile devices and digital solutions for the life sciences and clinical research sectors. He has been a pivotal figure in the company's development since its incorporation on May 6, 2020.

Under Steve's leadership, Inventus Group has focused on delivering end-to-end device lifecycle management tailored for clinical trials. The company's services include provisioning customized mobile devices, implementing electronic Clinical Outcomes Assessment (eCOA) and electronic Patient-Reported Outcomes (ePRO) solutions, ensuring secure data collection compliant with EU GDPR and international standards, and promoting sustainable device recycling and redeployment strategies.

Steve's strategic vision emphasizes innovation, compliance with international standards, and sustainable practices in device lifecycle management, positioning Inventus Group as a key player in the intersection of technology and clinical research.

Under his guidance, Inventus Group has expanded its global footprint, establishing offices and logistics centers in the United Kingdom, Austria, the United States, Hong Kong, China and the Middle East. This international presence supports the company's mission to streamline clinical trials through technology-driven solutions.

A competently skilled, flexible, dependable, hard-working, conscientious and ambitious clinical research professional with a solid employment history (including 10 years clinical trial management experience).
Hands-on responsibility for the leadership and conduct of clinical trials either through fully in-sourced, fully outsourced or hybrid operational model. Management and execution of Phase I-IV oncology and immuno-oncology clinical trials including the direction, planning, execution and interpretation of clinical trials under ICH/Good Clinical Practices.
Experience within Biotechs, Pharma, CRO and University Investigator led research studies in Phase I - IV trials.
Possess a thorough understanding of cross-functional clinical processes including data management, drug safety and regulatory affairs and have demonstrated the ability to lead a cross-functional team in a matrix environment.
Assists in the development and implementation of strategy, policies and procedures. Manage aspects of external vendor contracts including CRO.

Therapeutic areas worked in including Oncology, Infectious disease, Neurology, Vaccines, Cardiovascular, Diabetes and Dermatology.
Proficiency in Microsoft Office programs, a number of clinical trial management, safety database and document repository systems with the ability to pick up new skills and learn quickly.
Specialties: Clinical Trial Management, Data Management, study start up, ethics and regulatory submission, Trial Master File & Investigator site File maintenance.

Asiyah Nawab, MSc, is an Analyst at GlobalData’s London office with the Immunology team. She is involved in the production of in-depth forecasting reports, opportunity assessments, and competitive landscape analysis reports for immunology-related areas. Additionally, Asiyah has extensive research experience in the field of Pharmaceutics, with her research in the encapsulation of drugs within microparticles using emulsion electrospraying, supplemented through in vitro bacterial studies. Asiyah holds a Master of Science in Pharmaceutics from University College London (UCL), and a Bachelor’s degree in Biochemistry from King’s College London.

Medical Doctor, Clinical Pharmacologist and Medical Director of VCTC, a patient centric clinical trial site located in the UK and Spain, dedicated to making clinical research accessible.

Eleanor McLaurin, Solution Specialist for Medidata has spent over 20 years in the Life Sciences industry. Eleanor supports organisations to create efficiencies throughout the clinical development and regulatory lifecycle through adoption of transformational technologies and data driven clinical and regulatory development approaches. Eleanor has spent the last 6 years working with organisations to leverage practical applications of AI and to implement data strategies which enable reliable generation of evidence and insights for internal oversight as well as for regulatory inspections and submissions.